Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Mann

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancerYing Cheng, Qing Zhou, Baohui Han, et al.
Clinical Pharmacology and Therapeutics|October 1, 2023
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON StudyJimmy Zhijian He, Vincent Duval, Petra Jauslin, et al.
British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.
Cancer|December 5, 2018
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studiesMyung-Ju Ahn, Chun-Ming Tsai, Frances A Shepherd, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2024
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL StudyShun Lu, Lin Wu, Qiming Wang, et al.
Gynecologic Oncology|January 3, 2016
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2023
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION StudyMyung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung CancerSuresh S Ramalingam, James C-H Yang, Chee Khoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 22, 2018
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian SubsetByoung Chul Cho, Busayamas Chewaskulyong, Ki Hyeong Lee, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancerYing Cheng, Qing Zhou, Baohui Han, et al.
Clinical Pharmacology and Therapeutics|October 1, 2023
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON StudyJimmy Zhijian He, Vincent Duval, Petra Jauslin, et al.
British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.
Cancer|December 5, 2018
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studiesMyung-Ju Ahn, Chun-Ming Tsai, Frances A Shepherd, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2024
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL StudyShun Lu, Lin Wu, Qiming Wang, et al.
Gynecologic Oncology|January 3, 2016
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2023
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION StudyMyung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung CancerSuresh S Ramalingam, James C-H Yang, Chee Khoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 22, 2018
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian SubsetByoung Chul Cho, Busayamas Chewaskulyong, Ki Hyeong Lee, et al.
Pageof 6